Sign Up Today and Learn More About Ajax Therapeutics Stock
Invest in or calculate the value of your shares in Ajax Therapeutics or other pre-IPO companies through EquityZen's platform.
Ajax Therapeutics Stock (AJTH)
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
About Ajax Therapeutics Stock
Founded
2019
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Ajax Therapeutics Press Mentions
Stay in the know about the latest news on Ajax Therapeutics
Macrocyclic heteroaromatic inhibitors of jak2
patents • Feb 01, 2026
5,6 bicyclic heteroaromatic inhibitors of jak2
patents • Feb 01, 2026
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
businesswire • Jan 13, 2026
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
biospace • Dec 10, 2025
Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
globenewswire • Dec 10, 2025
Ajax Therapeutics Management
Leadership team at Ajax Therapeutics
Board Member
Amit Sinha
CEO
Martin Vogelbaum
Join now and verify your accreditation status to gain access to:
- Ajax Therapeutics Current Valuation
- Ajax Therapeutics Stock Price
- Ajax Therapeutics Management
- Available deals in Ajax Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ajax Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ajax Therapeutics Revenue and Financials
- Ajax Therapeutics Highlights
- Ajax Therapeutics Business Model
- Ajax Therapeutics Risk Factors
- Ajax Therapeutics Research Report from SACRA Research
Trading Ajax Therapeutics Stock
How to invest in Ajax Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ajax Therapeutics through EquityZen funds. These investments are made available by existing Ajax Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Ajax Therapeutics stock?
Shareholders can sell their Ajax Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 52K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
